Saudi Arabia Loan Aggregator Market Report 2025: Retail Digital Payments Hit 70% as Tech Adoption Transforms Saudi Financial Services - Competition, Forecast & Opportunities to 2030
Saudi Arabian Loan Aggregator Market
Dublin, May 16, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Loan Aggregator Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to ResearchAndMarkets.com's offering.
The Saudi Arabian loan aggregator market, valued at USD 43.65 million in 2024, is expected to reach USD 63.78 million by 2030, growing at a CAGR of 6.58%. Significant growth is anticipated due to increased digitalization, fintech advancements, and regulatory backing from the Saudi Central Bank (SAMA). Consumers are increasingly using online platforms for seamless loan comparisons, enhancing market competition and transparency.
As digital banking and AI-driven financial services become more prominent, user experience and loan accessibility are improving. The collaboration between banks, fintech firms, and aggregators is expected to further propel market expansion by offering personalized loan options and streamlining borrowing processes for individuals and businesses.
The Saudi insurance sector also shows robust potential, with a 26.9% increase in Gross Written Premiums (GWP) reported by SAMA in 2022. The Financial Sector Development Program (FSDP) targets an increase in GWP as a share of non-oil GDP to 2.4% by 2025 and 4.3% by 2030, positioning it as a key contributor to the Saudi Arabia loan aggregator market.
Key Market Drivers
Digital Transformation and Fintech Adoption: Digital banking services have surged, integrating technology-driven solutions to enhance customer experiences. Loan aggregators now leverage AI, big data, and automation to provide tailored loan options, reducing the effort required to find suitable financing. By 2023, digital transactions accounted for 70% of retail payments, indicating a strong shift in consumer behavior and accelerating fintech adoption.
Key Market Challenges
Data Security and Privacy Concerns: Safeguarding sensitive consumer data remains a primary challenge. Despite SAMA's strict data protection regulations, maintaining robust cybersecurity frameworks is crucial for fintech companies and aggregators. Investments in encryption technologies and compliance with Saudi Arabia's Personal Data Protection Law (PDPL) are essential to building consumer trust.
Key Market Trends
Expansion of Islamic Finance Loan Aggregators: As a global hub for Islamic finance, Saudi Arabia sees growing demand for Shariah-compliant lending solutions. Loan aggregator platforms are incorporating Islamic finance products, leveraging AI-driven compliance checks and blockchain-based smart contracts, aligning with Saudi Arabia's Vision 2030 initiative.
Key Market Players
Creative Future for Digital Brokerage
Lendo Saudi Arabia
Foras Debt Crowdfunding Company
Bonoky
Digital Debt Crowdfunding Company (Raqamyah)
Tamam Financing Co.
Saudi Digital Payment Company (STC Pay)
Amlak International Finance Company
HALA Payments Company
Tazapay Pte. Ltd.
Report Scope
Loan Type:
Home Loans
Credit Cards
Personal Loan
Auto Loan
Others
Mode of Operation:
Online
Offline
Region:
Northern & Central
Western
Southern
Eastern
Key Attributes:
Report Attribute
Details
No. of Pages
81
Forecast Period
2024 - 2030
Estimated Market Value (USD) in 2024
$43.65 Million
Forecasted Market Value (USD) by 2030
$63.78 Million
Compound Annual Growth Rate
6.5%
Regions Covered
Saudi Arabia
For more information about this report visit https://www.researchandmarkets.com/r/ytkgdx
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Saudi Arabian Loan Aggregator Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hypebeast
an hour ago
- Hypebeast
The Slow Death of the Contemporary Art Gallery
The contemporary art gallery as we know it is dying. In cities like New York and Los Angeles, dedicated spaces that once buzzed with foot traffic and formal openings are now struggling with rising rents and changing expectations. The old model, where a gallery does everything for its artists, feels like it's falling apart. Big gallery chains, the ones built on endless art fairs, multiple cities and huge rosters of artists, are losing their grip. Last month, Tim Blum announced he would close his Blum & Poe galleries in L.A. and Tokyo and even stop plans for a new one in Tribeca. He was blunt about the reason: 'This is not about the market. This is about the system,'he told ARTnews, pointing out that collectors have more power than ever to negotiate. His decision echoes a wider feeling across the industry with many giving up on the idea of building giant gallery empires. You can see this shift happening at major events. The latestArt Baselconfirmed that galleries are showing more mid-priced work, not just the massive, ultra-expensive pieces they once counted on. A recentreport from Art Basel and UBSshowed that while the overall art market shrank last year, the number of actual sales went up. It's a clear signal that the business is no longer just about a small group of big spenders, it's now about reaching a wider audience at lower price points. 'The old model was built on scarcity and prestige. The new one runs on access and attention.' A significant force behind this change is the shifting demand for different types of art. The once-dominant 'blue-chip' artists, masters whose work commanded staggering prices, are no longer the only game in town. Collectors are increasingly turning their attention to 'red-chip' artists, a new class of talents whose value is built on viral hype and cultural relevance rather than institutional endorsement. These artists are attractive for two main reasons: their work is often more accessible and affordable, and it brings fresh, diverse cultural perspectives that feel relevant and exciting to a global audience. This hunger for new voices and unconventional methods is reshaping the market. A key example isOlaolu Slawn, a London-based artist who sold out his solo show,I present to you, Slawn, at the Saatchi Yates gallery in 2024 by creating and selling 1,000 individual, more accessible pieces, an approach that challenges the fine art world's focus on scarcity and prestige. A separate but related trend sees celebrities entering the art market with their own work, often commanding high prices based on their fame. Actor Adrien Brody is a notable example. His art, which he described is about celebrating the little nuances in life has sold for significant amounts, as per a convo withInterview Magazine. For instance, a painting he created of Marilyn Monroe was sold at a Cannes gala auction for $425,000 USD, illustrating how star power can directly translate into commercial value. However, his work has drawn sharp criticism from the industry, with critics often labeling it as kitschy and derivative. One critic writing forARTnewsdescribed his work as having a 'faux naïve aesthetic' and 'mediocre production value,' while others have accused him of cheaply appropriating the styles of Jean-Michel Basquiat and Andy Warhol. As the old guard shrinks, smaller galleries are finding new ways to thrive. In New York,Tiwa Galleryshows self-taught artists in a relaxed space, rejecting flashy Landddcombines Latin American crafts with immersive events. In L.A.,Marta galleryblends art and design right into everyday life. These new spaces care more about quiet, genuine connection than putting on a spectacle. Retail is also becoming a new kind of gallery. Stores like South Korea's Gentle Monster and London's Dover Street Market are blurring the lines between art and commerce, transforming shopping into an immersive cultural experience. Gentle Monster's stores are famous for their fantastical, ever-changing installations, from surreal kinetic sculptures to robotic figures that draw in visitors who are just as interested in the art as they are in the eyewear. Dover Street Market, founded by Comme des Garçons's Rei Kawakubo, is a 'beautiful chaos' where each brand and artist is given a dedicated space to create a unique installation, turning the store into a constantly evolving exhibition. By blending high-end retail with cutting-edge art and design these spaces offer a new kind of public access to creativity, making the gallery experience a part of a commercial transaction rather than a separate cultural outing. 'If your space is fueled by DJs and cocktails, maybe it isn't really a gallery anymore.' It's clear that going to a gallery is no longer the only way to see or buy art. Today, buyers can just scroll on their phones and purchase work directly from studios or social media. This instant access has replaced the slow dance of white-cube shows and champagne previews. Some galleries are trying to keep up, creating online art drops and hosting pop-ups in different retail spaces. But others are pushing back, as one veteran gallerist puts it: if your space is fueled by DJs and cocktails, maybe it isn't really a gallery anymore. Art isn't disappearing. It's just moving, becoming more accessible and less tied to one physical location. The old model was built on scarcity and prestige. The new one runs on access and attention. The question isn't whether galleries will survive, but which ones can change fast enough to matter.
Time Business News
5 hours ago
- Time Business News
Next-Generation Approaches to Hematologic Malignancies
Hematologic malignancies are cancer that affect blood, bone marrow, and lymphatic systems including leukemia, lymphoma and multiple myeloma. These cancers disrupt normal blood cell production and immune function. The growth of the hematologic malignancy market is inspired by increasing the prevalence of global cancer, increasing target remedies and immunotherapy, progression in clinical technologies and expanding research in individual medicine. Additionally, increasing awareness, better healthcare infrastructure, and oncology contribute to more investment market expansion in drug development. Key Growth Drivers and Opportunities Increasing the Prevalence of Global Cancer: The increasing global spread of cancer greatly enhances the growth of the market of hematologic malignancies, as blood -related cancer, such as leukemia, lymphoma and multiple myeloma, become a large part of cancer worldwide. As more individuals are affected by these conditions, there is an increasing demand for accurate diagnosis, advanced treatment options and long -term disease management solutions. In cases, this increase encourages drug companies and research institutes to invest in innovative remedies such as targeted treatment, immunotherapy and CAR-T cell therapy. Additionally, high cancer phenomena motivate governments and healthcare systems to increase screening programs and to reach oncology. Challenges Hematologic malignancies markets face several borders, including high cost of advanced treatments such as car-T cell treatment and targeted drugs, which can restrict access to patients in low- and moderate-income areas. Complex regulatory approval, long clinical testing procedures, and severe side effects or ability to resist also face significant challenges. Additionally, limited availability of specialized clinical equipment and lack of efficient health care professionals in some fields obstruct timely and accurate diagnosis, overall treatment affects results and slows down market development. Innovation and Expansion Kyowa Kirin and Kura Oncology Collaborate to Create Ziftomenib for Acute Leukemias In November 2024, in order to develop and market ziftomenib, Kura's selective oral menin inhibitor, which is being researched for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies, Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. announced they have formed a global strategic partnership. Kura will get USD 330 million up front as part of the deal, and it anticipates receiving up to USD 420 million in near-term milestone payments, including one when ziftomenib is introduced in the monotherapy relapsed/refractory (R/R) context. Merck Launched Phase III Trials for Novel Treatments for Blood Disorders and Cancer In January 2024, With the start of pivotal Phase III studies for four new candidates for solid tumors and hematologic malignancies, Merck's strong oncology and hematology portfolio is progressing. Essential thrombocythemia (ET), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), non-small cell lung cancer (NSCLC), some patients with endometrial carcinoma who have already received treatment, and metastatic castration-resistant prostate cancer (mCRPC) are among the conditions for which the company announced active enrollment for investigational medications. The firm is committed to ongoing research to broaden our portfolio of oncology treatments in order to continue addressing unmet needs in cancer care. The company has a rich history of transforming groundbreaking science into medicines that save and enhance lives worldwide. Inventive Sparks, Expanding Markets The key players operating the hematologic malignancies market includes, Johnson & Johnson Services Inc., Pfizer Inc., Novartis AG, AbbVie Inc., GlaxoSmithKline PLC., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Inc., Celgene Corporation, F. Hoffman-La Roche Ltd., Takeda Pharmaceutical Company Limited., and others. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Yahoo
7 hours ago
- Yahoo
Oligonucleotide CDMO Market to Soar USD 18.37 Billion at 21.83% Strong CAGR by 2034
The global oligonucleotide CDMO market is valued at USD 3.11 billion in 2025 and is projected to reach approximately USD 18.37 billion by 2034, expanding at a CAGR of 21.83% over the forecast period. Ottawa, Aug. 08, 2025 (GLOBE NEWSWIRE) -- According to a study by Towards Healthcare, a sister company of Precedence Research, the global oligonucleotide CDMO market size to grow from USD 2.55 billion in 2024 and is expected to expand USD 18.37 billion by 2034. The growth of the market is driven by the increased demand for specialized techniques, which are technologically advanced due to the growing prevalence of chronic diseases in the region. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the oligonucleotide CDMO market in 2024. Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. By service, the contract manufacturing segment led the market in 2024. By service, the contract development segment is estimated to achieve significant growth during the forecast period. By type, the ASO segment held a significant share of the market in 2024. By type, the siRNA segment is expected to grow significantly during the forecast period. By application, the therapeutic segment held the largest share of the oligonucleotide CDMO market in 2024. By application, the research segment is anticipated to grow at a significant rate during the forecast period. By end-use, the pharma segment held a major share of the market in 2024. By end-use, the biotech segment is anticipated to achieve a significant share of the market during the forecast period. Market Overview & Potential An oligonucleotide CDMO (Contract Development and Manufacturing Organization) specializes in offering comprehensive services for developing and manufacturing short oligonucleotides, which are synthetic nucleic acid sequences used in various biotech and pharmaceutical applications. These organizations provide expertise in custom synthesis, process development, scale-up, and GMP manufacturing of oligonucleotides. You can place an order or ask any questions, please feel free to contact us at sales@ What Is the Growth Potential Responsible for The Growth of The Oligonucleotide CDMO Market? The growth of the market is driven by the growing demand for personalized medicines and RNA therapeutics, which demand specialized manufacturing capabilities, which fuels the growth of the market. The increasing prevalence of chronic diseases, especially cancer and cardiovascular diseases, with advancements in oligonucleotide manufacturing to improve synthesis technologies with automated techniques, drives the growth of the market. Other key growth drivers are government support and funding, increased investment in biotechnology, globalization, and increased collaboration boost the growth of the market. What Are the Emerging Trends in the Oligonucleotide CDMO Market? Growing Demand for Oligo-based Therapies: Oligonucleotides, including antisense oligonucleotides and small interfering RNAs, are increasingly recognized as therapeutic agents because of their targeted action and specificity. Focus on Precision Medicine: The shift toward personalized treatments designed for individual patients is boosting the need for specialized oligonucleotide therapies. Increased FDA Approvals: The rising number of FDA approvals for oligonucleotide-based drugs, such as Qalsody for ALS, further fuels market growth and stimulates innovation. Cost Efficiency and Expertise: Outsourcing to CDMOs enables companies to utilize specialized knowledge and potentially lower costs associated with in-house manufacturing, particularly for complex processes. What Are the Major Challenges Facing the Oligonucleotide CDMO Market? The market encounters several notable challenges, mainly due to manufacturing complexity, regulatory obstacles, and the need for advanced expertise and infrastructure. Scaling from research to commercial volumes, achieving high purity, and ensuring delivery efficiency to target sites are significant hurdles. Evolving regulatory requirements and the need for specialized skills in oligonucleotide synthesis, purification, and conjugation also contribute to the difficulty. Get the latest insights on life science industry segmentation with our Annual Membership: Regional Insights Why Did North America Lead the Oligonucleotide CDMO Market in 2024? North America held a dominant position in 2024 due to its well-established research facilities, substantial R&D investments in peptide and oligonucleotide therapies, and a higher prevalence of chronic diseases. The demand for biopharmaceuticals like oligonucleotides and peptides supports this growth. North American CDMOs are well-equipped to meet this demand by providing specialized development and manufacturing services for these complex compounds. The market expansion is driven by ongoing investments from pharmaceutical and biotech firms into R&D, often through partnerships with CDMOs to access advanced infrastructure and expertise. High R&D investment, advanced biotech infrastructure, rising chronic disease prevalence, and strong pharmaceutical industry demand drive U.S. oligonucleotide CDMO growth. Regulatory clarity from the FDA, increasing personalized medicine focus, and government support for genomics research further enhance market expansion, fostering innovation and strategic collaborations with contract manufacturers. Government incentives for biotechnology, a skilled scientific workforce, and growing demand for precision medicine propel Canada's oligonucleotide CDMO sector. Strong academic-industry partnerships, supportive regulatory frameworks, and increasing investments from global pharma companies in Canadian CDMO facilities promote innovation, clinical trials, and manufacturing scalability within the country. Why Is Asia Pacific Projected to Show Rapid Growth in the Oligonucleotide CDMO Market? Asia Pacific is anticipated to be the fastest-growing region for oligonucleotide CDMOs during the forecast period. Countries like China, Japan, India, and South Korea are leading due to their large populations, focus on biopharmaceutical innovation, and strong healthcare investments. The region's market share has notably increased over recent years, supported by economic growth and rising prosperity, making it attractive for pharmaceutical outsourcing. This growth is further fueled by increased R&D funding and improvements in healthcare infrastructure. Rapid biotechnology expansion, government funding, and a large patient population fuel oligonucleotide CDMO growth in China. Domestic pharma companies increasingly outsource production, while favorable policies, infrastructure development, and cost advantages attract global partnerships. China's focus on RNA therapeutics and local innovation also accelerates CDMO sector maturation and competitiveness. Low manufacturing costs, a strong generic pharmaceutical base, and a growing talent pool drive India's oligonucleotide CDMO growth. Government initiatives supporting biotech innovation, rising contract research demand, and increased interest from Western firms in Indian CDMOs contribute. The expanding clinical trial ecosystem further enhances market attractiveness and outsourcing potential. Become a valued research partner with us - Segmental Insights Which Service Segment Dominated the Oligonucleotide CDMO Market in 2024? The contract manufacturing segment led the market in 2024, driven by the rising need for wide-scale, cGMP-compliant oligonucleotide APIs for clinical and commercial use. To meet the growing demand for ASOs, siRNAs, and mRNA-based therapies, CDMOs equipped with advanced solid-phase synthesis, automated fill-finish systems, and high-throughput purification are vital. This leadership is reinforced by pharmaceutical companies' reliance on CDMOs for high-purity, scalable, and globally compatible manufacturing solutions, driven by strict regulations and expansion challenges. This led to a growing and expanding influence on market growth. The contract development segment is estimated to achieve significant growth during the forecast period. Encompassing services like preclinical development, formulation, process development, and analytical techniques. These services are crucial for optimizing production processes and ensuring the safety and quality of oligonucleotides and peptides. R&D in oligonucleotide therapies is a key investment focus for pharma and biotech companies. Partnering with CDMOs allows these companies to reduce costs and accelerate product development, focusing on their core competencies. How did ASO Segment Dominated the Oligonucleotide CDMO Market in 2024? The ASO segment held a significant share of the market in 2024. Over the decades, the biotech and pharma industries have developed innovative approaches to target disease-related proteins, demanding innovation and development of new technologies and forms of products, which increases the demand for the market. RNA therapeutics, especially antisense oligonucleotides, have made significant progress in the market. Several ASO-based drugs are already FDA-approved, with many more under clinical testing. These factors support the growth and expansion of the market. The siRNA segment is expected to grow significantly during the forecast period. SiRNA technologies offer speed and specificity, helping to overcome preclinical drug development hurdles, which fuels the demand for the market. They currently assist in identifying the most promising pharmacological targets for specific diseases and are being explored for new, potent applications in drug candidate prioritization. These applications and benefits offered by the segment promote the growth and expansion of the market. Which Application Segment Dominated the Oligonucleotide CDMO Market in 2024? The therapeutic segment held the largest share of the market in 2024. Approaches have been developed to enhance the pharmacokinetics and pharmacodynamics of oligonucleotides. Historically targeted at rare diseases and niche markets, oligonucleotides now benefit large patient groups. The field is rapidly expanding despite fluctuations, with 44 companies having compounds in late-stage clinical trials or on the market. Major players include Johnson & Johnson, Roche, Novartis, and AstraZeneca, alongside specialized biotech firms like Ionis Pharmaceuticals and Alnylam Pharmaceuticals. Concurrently, there has been notable activity in oligonucleotide patents and applications influencing the growth. The research segment is anticipated to grow at a significant rate in the oligonucleotide CDMO market during the forecast period, with contributions from research institutions impacting early-stage research, innovative technologies, and scientific breakthroughs. These institutions are vital in identifying therapeutic potentials, fostering partnerships with CDMOs and pharma companies, and influencing market dynamics. Advances in distribution, analytics, and synthesis are driving market expansion, and published research influences development and manufacturing strategies. How did the pharma Segment dominate the Oligonucleotide CDMO Market In 2024? The pharma segment accounted for a major market share in 2024. The advent of oligonucleotide therapies has revolutionized medicine, with several approved in the US and EU. These include a mix of single and double-stranded polydeoxyribonucleotides, six siRNAs, twelve ASOs, and one aptamer. The growing pharma sector and the application of oligonucleotides increase the demand for manufacturing and production, which contributes to the growth and expansion of the market. The biotech segment is also expected to claim a significant market share, enabled by protein-DNA functionalization through covalent bonding. This technology facilitates the creation of therapeutic molecules with potential applications for diseases like AIDS and cancer. The ongoing research and development in the biotech sector further propels the growth and expansion of the market. Recent Developments in the Oligonucleotide CDMO Market In April 2025, Sumitomo Chemical announced the launch of its new company, Sumitomo Chemical Advanced Medical Solutions America LLC, in Massachusetts to serve as its Oligonucleotide CDMO2 business. The company will provide gRNA samples to customers by August 2025. In July 2024, Agilent Technologies announced a strategic agreement to acquire BioVectra, a specialized CDMO, for $925 million. The acquisition was made to build Agilent Technologies' CDMO specialization in oligonucleotides and CRISPR therapeutics, expanding its portfolio of services and bringing world-class capabilities to support gene editing. Browse More Insights of Towards Healthcare: The global life science CDMO market is witnessing rapid expansion, with revenues projected to reach several hundred million dollars by the end of the forecast period (2025–2034). The veterinary CRO and CDMO market was valued at USD 7.17 billion in 2024, is expected to reach USD 7.77 billion in 2025, and is projected to climb to approximately USD 16.13 billion by 2034, growing at a CAGR of 8.43% during 2025–2034. The advanced therapy medicinal products (ATMP) CDMO market stood at USD 6.73 billion in 2024, increased to USD 7.99 billion in 2025, and is forecast to surge to USD 37.27 billion by 2034, registering a CAGR of 18.82% from 2025 to 2034. The investigational new drug CDMO market was valued at USD 5.29 billion in 2024, rose to USD 5.66 billion in 2025, and is anticipated to reach USD 10.34 billion by 2034, expanding at a CAGR of 6.97% between 2025 and 2034. The mRNA therapeutics CDMO market was worth USD 4.62 billion in 2024, increased to USD 5.15 billion in 2025, and is projected to grow to USD 13.63 billion by 2034, recording a CAGR of 11.37% during 2025–2034. The CDMO services for pharma and biotech market is experiencing substantial growth from 2024 to 2034, fueled by the increasing outsourcing trend among pharmaceutical and biotechnology companies. The CDMO aseptic filling solutions market is set for strong growth throughout the forecast period, driven by rising demand for sterile manufacturing capabilities and specialized injectable therapies. The active pharmaceutical ingredients (API) CDMO market was valued at USD 127.45 billion in 2024, increased to USD 136.92 billion in 2025, and is estimated to reach USD 260.98 billion by 2034, growing at a CAGR of 7.43% from 2025 to 2034. The small molecule CDMO market stood at USD 72.81 billion in 2024, rose to USD 78.01 billion in 2025, and is forecast to hit USD 145.12 billion by 2034, expanding at a CAGR of 7.14% during 2025–2034. The topical drugs CDMO market was worth USD 46.32 billion in 2024, increased to USD 51.62 billion in 2025, and is expected to reach USD 136.71 billion by 2034, registering a CAGR of 11.43% between 2025 and 2034. Top Companies and Their Contributions to the Market Contributions & Offerings to the Oligonucleotide CDMO Market Bachem A global leader in peptide and oligonucleotide synthesis, Bachem offers full CDMO services including development, GMP manufacturing, and analytics. Thermo Fisher Scientific Inc. Provides end-to-end oligonucleotide services, from preclinical to commercial scale, leveraging advanced technologies and global infrastructure. Agilent Technologies, Inc. Offers custom oligo synthesis and quality control platforms, supporting therapeutic development with scalable manufacturing capabilities. EUROAPI Delivers active pharmaceutical ingredient (API) production, including oligonucleotides, with a focus on quality, sustainability, and innovation. ST Pharm Specializes in large-scale GMP oligonucleotide manufacturing, supplying APIs globally with expertise in modified nucleic acids and cGMP compliance. Kaneka Eurogentec S.A. Provides custom manufacturing of therapeutic oligonucleotides, with cGMP-grade synthesis, formulation, and analytical support. Ajinomoto Co., Inc. Leverages proprietary biotechnologies for oligonucleotide production, offering scale-up and process development through its CDMO division. Aurigene Pharmaceutical Offers integrated CDMO services including oligonucleotide synthesis, analytical development, and GMP manufacturing for global biopharma clients. Syngene International Provides end-to-end oligo development and manufacturing, supporting early-stage to commercial scale with regulatory expertise. PolyPeptide Group Recently expanded into oligonucleotide CDMO services, combining peptide and oligo synthesis capabilities with advanced regulatory compliance. Key Players in Oligonucleotide CDMO Market Bachem Thermo Fisher Scientific Inc. Agilent Technologies, Inc. EUROAPI ST Pharm Kaneka Eurogentec S.A. Ajinomoto Co., Inc. Aurigene Pharmaceutical Services Ltd. Syngene International Limited PolyPeptide Group WuXi AppTec Eurofins Scientific GenScript Lonza Danaher Corporation Segments Covered in The Report By Service Contract Manufacturing Clinical Commercial Contract Development By Type ASO siRNA CPG Oligos gRNA By Application Therapeutic Research Diagnostics By End-User Pharma Biotech By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Immediate Delivery Available | Buy This Premium Research @ Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
